A multicenter, open-label trial to investigate the safety and tolerability of intravenous SPM 927 [lacosamide] as replacement for oral SPM 927 in subjects with partial seizures with or without secondary generalization.

Trial Profile

A multicenter, open-label trial to investigate the safety and tolerability of intravenous SPM 927 [lacosamide] as replacement for oral SPM 927 in subjects with partial seizures with or without secondary generalization.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 22 Oct 2014

At a glance

  • Drugs Lacosamide (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Registrational
  • Sponsors UCB
  • Most Recent Events

    • 07 Dec 2009 Results were presented at the 63rd annual meeting of the American Epilepsy Society in Boston, according to a UCB media release.
    • 18 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top